WARRANT TO PURCHASE COMMON STOCK INHIBRX BIOSCIENCES, INC.Warrant Agreement • April 25th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 25th, 2024 Company Industry JurisdictionTHIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [·] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from INHIBRX BIOSCIENCES, INC., a Delaware corporation (the “Company”), up to [·] shares of common stock, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 25th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledApril 25th, 2024 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [•], by and between INHIBRX BIOSCIENCES, INC., a Delaware corporation (the “Company”), and [•] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
Re: Employment Agreement Assignment and AssumptionEmployment Agreement Assignment and Assumption • April 25th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledApril 25th, 2024 Company IndustryIn connection with the spin-off of Inhibrx Biosciences, Inc. (“Inhibrx Biosciences”), Inhibrx, Inc. (“Inhibrx”) hereby assigns its respective rights and obligations under each of the Second Amended and Restated Executive Employment Agreement, by and between you and Inhibrx, effective as of January 1, 2023 (your “Employment Agreement”), the compensation update letter, by and between you and Inhibrx, dated as of January 4, 2024 (your “Compensation Letter”) and the Proprietary Information and Inventions Agreement, by and between you and Inhibrx, dated as of October 1, 2018 (your “PIIA”) to Inhibrx Biosciences, and Inhibrx Biosciences accepts and assumes such rights and obligations, effective as of the Distribution Date (as defined in the Separation and Distribution Agreement by and among Inhibrx Biosciences, Inhibrx and others dated as of January 22, 2024, as in effect from time to time) (collectively, the “Assignment”). The Distribution Date is currently anticipated to occur on or about
EMPLOYMENT AGREEMENTEmployment Agreement • June 11th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledJune 11th, 2024 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is effective as of May 30, 2024 (the “Effective Date”) by and between Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), and Brendan Eckelman (“Employee”). The Company and Employee are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 30th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 30th, 2024 Company Industry JurisdictionThis REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 29, 2024, is made by and among Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), and the Holders listed on Schedule 1 hereto (individually, a “Holder” and collectively, the “Holders”).
TRANSITION SERVICES AGREEMENT BETWEEN INHIBRX BIOSCIENCES, INC. AND INHIBRX, INC. DATED MAY 29, 2024Transition Services Agreement • May 30th, 2024 • Inhibrx Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMay 30th, 2024 Company Industry JurisdictionThis TRANSITION SERVICES AGREEMENT, dated May 29, 2024 (as amended, modified or supplemented from time to time in accordance with its terms, this “Agreement”), is made and entered into by and between Inhibrx, Inc., a Delaware corporation (“RemainCo”), and Inhibrx Biosciences, Inc., a Delaware corporation (“SpinCo”). Unless otherwise defined herein, all capitalized terms used herein shall have the same meanings as in the Separation Agreement (as defined below).